The postmenopausal osteoporosis market is estimated to be valued at US$ 4,747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Postmenopausal osteoporosis refers to a bone disease which causes loss of bone mass and density that occurs in women after menopause. Major products available in the market are bisphosphonates, selective estrogen receptor modulators (SERMs), monoclonal antibodies and anabolic agents. Bisphosphonates are the most widely prescribed drugs to treat postmenopausal osteoporosis.
Market Dynamics:
The postmenopausal osteoporosis market is expected to rise owing to the increasing geriatric population across the globe as aging causes decline in estrogen levels in women which leads to increased bone loss. According to the United Nations, the population aged 60 years and above is expected to reach 2.1 billion by 2050 from 1.4 billion in 2030. Additionally, growing awareness regarding osteoporosis care, diagnosis and management programs worldwide will also foster market growth during the forecast period. However, side effects associated with postmenopausal osteoporosis drugs and strict regulations for drug approval are some of the major factors that may hamper market growth.
SWOT Analysis
Strength:
Growing aging population suffering from osteoporosis is increasing the demand for treatment medications.
Advancements in research and development have led to the availability of more effective drugs for osteoporosis treatment.
Rising awareness about osteoporosis and bone health management is encouraging people to seek medical help.
Weakness:
High cost of osteoporosis medications make long-term therapy unaffordable for many patients.
Side effects associated with few osteoporosis drugs reduce patient compliance.
Opportunity:
Untapped markets in developing regions offer ample room for market expansion.
Development of new drug formulations and delivery methods can enhance treatment effectiveness.
Growing healthcare expenditure in emerging economies will boost the adoption of osteoporosis medications.
Threats:
Patent expiration of blockbuster drugs results in availability of generics, affecting revenues of innovator companies.
Stringent regulations for drug approval delay market entry of new products.
Key Takeaways
The global Postmenopausal Osteoporosis Market Growth is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period, due to increasing geriatric population suffering from osteoporosis.
Regional analysis:
North America currently dominates the market owing to rising incidence of osteoporosis and heavy R&D investments. However, Asia Pacific is anticipated to register fastest growth due to growing healthcare infrastructure and increasing healthcare expenditure in major countries like China and India.
Key players:
Key players operating in the postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung Bioepis, Radius Health, Inc., Alvotech, and AryoGen Pharmed.
Read More,
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian